Dishman Carbogen Amcis Share Price | Dishman Carbogen Amcis Stock Screener
DCAL
Pharmaceuticals
Share Price NSE
₹195.37
▼
-16.51 (-7.79%)
Share Price BSE
₹195.45
▼
-17.45 (-8.20%)
As of May 22, 2026, the Dishman Carbogen Amcis share price (NSE: DCAL) is ₹195.37 on NSE and ₹195.45 on BSE, down 7.79% from the previous close, with shares trading between ₹195.00 and ₹213.85, and a 52-week range of ₹129.97–₹314.00.
Check DCAL annual price range for the annual price range and momentum.
Use the Dishman Carbogen Amcis stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Dishman Carbogen Amcis Market Cap
₹3,045.51 Cr.
DCAL P/E Ratio (TTM)
23.40
Dishman Carbogen Amcis P/B Ratio
0.44
EPS (TTM)
₹0.21
Dividend Yield
-
Debt to Equity
0.41
DCAL 52 Week High
₹314.00
Dishman Carbogen Amcis 52 Week Low
₹129.97
Operating Margin
20.00%
Profit Margin
5.94%
DCAL Revenue (TTM)
₹724.00
EBITDA
₹149.00
Net Income
₹43.00
Total Assets
₹9,999.00
Total Equity
₹5,832.00
Dishman Carbogen Amcis Share Price Chart
Screen Dishman Carbogen Amcis share price with an interactive chart. Analyse DCAL price trends and volatility across different timeframes.
Dishman Carbogen Amcis Company Profile - Fundamental Screener
Screen Dishman Carbogen Amcis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for DCAL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE385W01011
Dishman Carbogen Amcis Balance Sheet Screener
Screen DCAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 9,999 | 9,581 | 9,454 | 8,638 | 8,366 | 8,200 | 7,329 | 7,177 | 6,593 |
| Current Assets | 2,200 | 1,928 | 1,918 | 1,839 | 1,704 | 1,779 | 1,554 | 1,546 | 1,245 |
| Fixed Assets | 7,055 | 6,724 | 6,188 | 5,773 | 5,698 | 5,678 | 5,098 | 5,066 | 4,852 |
| Liabilities | |||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2,243 | 1,399 | 1,845 | 1,669 | 1,377 | 916 | 751 | 891 | 786 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 5,832 | 5,628 | 5,810 | 5,549 | 5,699 | 5,715 | 5,379 | 5,107 | 4,814 |
| Share Capital | 31 | 31 | 31 | 31 | 31 | 31 | 32 | 32 | 0 |
| Reserves & Surplus | 5,800 | 5,596 | 5,778 | 5,518 | 5,668 | 5,684 | 5,347 | 5,075 | 4,814 |
Dishman Carbogen Amcis Income Statement Screener - Profit & Revenue Analysis
Screen Dishman Carbogen Amcis income statement and profit fundamentals.
Analyze DCAL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Dishman Carbogen Amcis share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 724 | 733 | 661 | 727 | 662 | 525 | 796 | 690 | 625 | 730 | 595 | 657 | 573 | 546 | 623 |
| Expenses | 575 | 570 | 504 | 607 | 595 | 500 | 645 | 542 | 613 | 602 | 529 | 610 | 559 | 452 | 535 |
| EBITDA | 149 | 163 | 157 | 120 | 67 | 25 | 151 | 148 | 13 | 128 | 66 | 47 | 14 | 94 | 88 |
| Operating Profit % | 20.00% | 19.00% | 23.00% | 16.00% | 9.00% | 4.00% | 18.00% | 21.00% | 1.00% | 17.00% | 10.00% | 6.00% | 2.00% | 16.00% | 13.00% |
| Depreciation | 79 | 81 | 84 | 84 | 85 | 71 | 72 | 72 | 76 | 70 | 75 | 80 | 84 | 75 | 80 |
| Interest | 42 | 43 | 42 | 46 | 31 | 32 | 37 | 49 | 24 | 29 | 28 | 33 | 16 | 19 | 20 |
| Profit Before Tax | 28 | 39 | 31 | -10 | -49 | -78 | 42 | 27 | -88 | 30 | -36 | -66 | -85 | 0 | -12 |
| Tax | -15 | 15 | -35 | 3 | 21 | 0 | 9 | 22 | -17 | 13 | 5 | -7 | -41 | -4 | -2 |
| Net Profit | 43 | 23 | 65 | -13 | -70 | -78 | 33 | 5 | -71 | 17 | -41 | -60 | -45 | 4 | -10 |
| EPS | 2.75 | 1.49 | 4.16 | -0.83 | -4.46 | -4.95 | 2.11 | 0.30 | -4.51 | 1.08 | -2.61 | -3.80 | -2.85 | 0.26 | -0.64 |
Dishman Carbogen Amcis Cash Flow Screener - Liquidity Fundamentals
Screen DCAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2012-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 375 | 379 | 266 | 355 | 513 | 585 | 282 | 226 | 303 | 154 |
| Investing Activities | -196 | -225 | -494 | -619 | -380 | -442 | -169 | -297 | -107 | -104 |
| Financing Activities | -102 | -22 | 250 | 130 | -11 | -98 | -102 | 78 | -137 | -68 |
| Net Cash Flow | 77 | 132 | 22 | -133 | 122 | 46 | 11 | 7 | 59 | -19 |
Dishman Carbogen Amcis Shareholding Pattern Screener
See Dishman Carbogen Amcis shareholding pattern with promoter, FII, and DII holdings.
Check Dishman Carbogen Amcis promoter holding and ownership changes for DCAL on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
| FII Holding | 7.45% | 9.49% | 9.93% | 8.07% | 7.66% | 8.70% | 8.04% | 8.17% |
| DII Holding | 1.63% | 1.26% | 1.27% | 1.37% | 1.27% | 2.37% | 1.48% | 1.23% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 27.20% | 25.31% | 25.36% | 26.84% | 27.31% | 25.17% | 27.10% | 27.43% |
| Other Holding | 4.40% | 4.62% | 4.11% | 4.39% | 4.44% | 4.45% | 4.06% | 3.85% |
| Shareholder Count | 49,009 | 50,757 | 49,744 | 49,455 | 48,481 | 50,656 | 53,683 | 55,280 |
Dishman Carbogen Amcis Share Dividend Screener - Share Yield Analysis
Check Dishman Carbogen Amcis dividend history with payout and yield data.
View Dishman Carbogen Amcis dividend details including ex-dates and amounts for DCAL stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.20 | 0.37% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹1.20 | 0.37% |
Dishman Carbogen Amcis Stock Index Membership
See which indices include Dishman Carbogen Amcis stock.
Check DCAL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Dishman Carbogen Amcis Market Events Screener - Corporate Actions
Get Dishman Carbogen Amcis corporate actions including splits, bonuses, and buybacks.
Check Dishman Carbogen Amcis stock events that may affect DCAL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 3.83% | ||
| Annual General Meeting | NA | -4.79% | ||
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | 10.31% |
| 2026-02-03 | 2026-02-03 | Quarterly Result Announcement | NA | 4.54% |
| 2025-11-04 | 2025-11-04 | Quarterly Result Announcement | NA | -0.44% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -0.81% |
| 2025-05-21 | 2025-05-21 | Quarterly Result Announcement | NA | 1.32% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -5.97% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -2.31% |
| 2017-03-27 | 2017-03-27 | Change Of Name | NA | - |
Dishman Carbogen Amcis Competitors Screener - Peer Comparison
Screen DCAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Dishman Carbogen Amcis Company Announcements - News Screener
Screen DCAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-21 | Board Meeting Intimation for Considering Take On Record & Approve The Audited Financial Results Of The Company For The Quarter And Year Ended 31/03/2026 & To Consider Evaluate And Approve The Proposal Of Availing ECB In The Form Of Unsecured Loan(S) From | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-20 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-02 | DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015 : Amendment In Terms Related To Financial Covenants For FY Ended 31St March 2026 In Respect Of Non-Convertible Debentures (NCDS) Issued Under ISIN INE385W07059 | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-18 | Board Meeting Outcome for BOARD APPROVES ISSUE OF SENIOR SECURED RATED LISTED REDEEMABLE TRANSFERABLE TAXABLE NON-CONVERTIBLE DEBENTURES AGGREGATING UP TO RS. 150 CRORES | - |
| 2026-03-15 | Board Meeting Intimation for Considering And Approving The Proposal Of Fund Raising By Way Of Issuance Of Non-Convertible Debentures By Way Of Private Placement Subject To Such Regulatory Or Statutory Approvals As May Be Required | - |
| 2026-02-23 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-02-20 | DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS 2015: COMPANYS WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS B.V. RECEIVED CERTIFICATE OF GMP COMPLIANCE FOR ITS VEENENDAAL SITE NETHERLANDS. | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-03 | Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2025 | - |
| 2026-02-03 | UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS LIMITED REVIEW REPORT FOR THE THIRD QUARTER ENDED 31/12/2025 | - |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-29 | Board Meeting Intimation for Considering Take On Record And Approve The Un-Audited Financial Results Of The Company For The Third Quarter Ended On 31St December 2025 | - |